Rene Haas, the chief executive of Arm Holdings, a Cambridge-based chip designer, stated that artificial intelligence (AI) will find a cure for cancer that humans cannot achieve within their lifetimes. Haas, who previously served on the board of AstraZeneca, explained that modeling the impact of cancer on DNA markers is currently too complex for both humans and existing AI technology. However, he believes that advancements in AI will eventually solve these challenges.
In an interview with the BBC, Haas also predicted the emergence of widespread humanoid robots within the next five years, although he noted that a shortage of chips is currently hindering the rapid growth of AI technology. He expressed skepticism about the potential for chip manufacturing to return to the UK, citing the high costs and specialized workforce required for chip fabrication.
Arm Holdings designs microchips used in various devices globally, including smartphones and cars. Earlier this summer, the company's share price reached a peak amid the AI boom, making it the most valuable UK-based company in history in cash terms.
Haas mentioned that AI's role in cancer research is becoming increasingly significant. Professor Chris Bakal from the Institute of Cancer Research highlighted that the focus should be on the quality of data fed into AI systems rather than the size of the computing infrastructure. He noted that training AI on data generated from patient samples could accelerate the development of new treatments.
Haas also discussed the potential of AI-powered robots in various sectors, such as manufacturing and cleaning, emphasizing their ability to learn and adapt to new tasks. While he acknowledged concerns about job displacement due to AI, he argued that the overall impact would lead to new opportunities rather than widespread job losses.
He pointed out that Arm's technology is currently utilized in half of the AI data centers worldwide and mentioned significant demand for their microchips, including a request from Meta for the development of the Arm AGI chip, which has seen over $2 billion in demand since its launch in March.
Despite challenges in chip supply, Haas remains optimistic about the future of AI and its applications. He noted ongoing plans for large data centers in France and the US, as well as potential projects in space, while emphasizing the need for more chip manufacturing facilities to support these developments. He reiterated that while some government officials have expressed concerns about Arm's sale to Japanese investors in 2016, the company continues to be a major employer in the UK, particularly in Cambridge.